0.8011
前日終値:
$0.8574
開ける:
$0.8444
24時間の取引高:
601.55K
Relative Volume:
0.74
時価総額:
$105.75M
収益:
$3.25M
当期純損益:
$-116.80M
株価収益率:
-0.2627
EPS:
-3.05
ネットキャッシュフロー:
$-98.17M
1週間 パフォーマンス:
-9.92%
1か月 パフォーマンス:
-29.73%
6か月 パフォーマンス:
-54.22%
1年 パフォーマンス:
-90.15%
Rapt Therapeutics Inc Stock (RAPT) Company Profile
名前
Rapt Therapeutics Inc
セクター
電話
(650) 489-9000
住所
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
RAPT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
RAPT
Rapt Therapeutics Inc
|
0.8011 | 105.75M | 3.25M | -116.80M | -98.17M | -3.05 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
485.89 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
549.28 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
587.59 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
230.50 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
228.14 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-26 | アップグレード | H.C. Wainwright | Neutral → Buy |
2024-11-13 | ダウングレード | Stifel | Buy → Hold |
2024-11-11 | ダウングレード | JP Morgan | Neutral → Underweight |
2024-11-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
2024-05-14 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
2024-05-10 | ダウングレード | Barclays | Overweight → Equal Weight |
2024-05-10 | ダウングレード | Guggenheim | Buy → Neutral |
2024-02-22 | ダウングレード | UBS | Buy → Neutral |
2024-02-21 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2024-02-21 | ダウングレード | JP Morgan | Overweight → Neutral |
2024-02-21 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2024-02-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2024-02-16 | 開始されました | Evercore ISI | Outperform |
2024-02-15 | 開始されました | Wolfe Research | Outperform |
2023-09-14 | 開始されました | Berenberg | Buy |
2023-08-09 | 開始されました | Stifel | Buy |
2023-06-15 | 開始されました | Barclays | Overweight |
2023-01-04 | 開始されました | Guggenheim | Buy |
2022-12-01 | 開始されました | Goldman | Buy |
2022-09-21 | 開始されました | CapitalOne | Overweight |
2022-05-24 | 再開されました | Cantor Fitzgerald | Overweight |
2021-12-09 | 開始されました | JP Morgan | Overweight |
2021-08-12 | 開始されました | SVB Leerink | Outperform |
2021-06-21 | 開始されました | Piper Sandler | Overweight |
2020-06-01 | 開始されました | H.C. Wainwright | Buy |
2020-05-19 | 開始されました | Cantor Fitzgerald | Overweight |
2020-04-13 | 開始されました | ROTH Capital | Buy |
2019-11-25 | 開始されました | BMO Capital Markets | Outperform |
2019-11-25 | 開始されました | UBS | Buy |
2019-11-25 | 開始されました | Wells Fargo | Outperform |
すべてを表示
Rapt Therapeutics Inc (RAPT) 最新ニュース
RAPT Therapeutics (RAPT) Strengthens Leadership with New VP for Clinical Development | RAPT Stock News - GuruFocus
RAPT Therapeutics Deepens Expertise in Allergic Diseases - GlobeNewswire
Top Allergy Expert Joins RAPT to Accelerate Novel Food Allergy Treatment Pipeline - Stock Titan
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Brokerages - Defense World
40,218 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Bought by Sei Investments Co. - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
Q1 EPS Forecast for RAPT Therapeutics Increased by Analyst - Defense World
Equities Analysts Set Expectations for RAPT FY2026 Earnings - Defense World
RAPT Therapeutics (NASDAQ:RAPT) Given “Buy” Rating at HC Wainwright - Defense World
H.C. Wainwright maintains $10 target on RAPT Therapeutics stock By Investing.com - Investing.com Canada
RAPT Therapeutics: Strategic Licensing and Strong Cash Position Support Buy Rating Despite Financial Loss - TipRanks
RAPT Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Double Feature: RAPT Therapeutics Takes Center Stage at Major Healthcare Investment Forums - StockTitan
Promising Developments and Strategic Trials Boost RAPT Therapeutics’ Buy Rating - TipRanks
RAPT Therapeutics Focuses on RPT904 Development in 2025 - TipRanks
RAPT Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RAPT THERAPEUTICS Earnings Results: $RAPT Reports Quarterly Earnings - Nasdaq
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
RAPT Therapeutics, Inc. SEC 10-K Report - TradingView
Rapt Therapeutics reports Q4 EPS ($1.14), consensus (36c) - TipRanks
Can RAPT's $231M War Chest and New Food Allergy Drug Transform Its Future? - StockTitan
RAPT Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
RAPT Therapeutics (RAPT) to Release Quarterly Earnings on Thursday - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Analysts - Defense World
Still Cautious Over RAPT Therapeutics’ Fresh Start With RPT904 (NASDAQ:RAPT) - Seeking Alpha
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
SG Americas Securities LLC Purchases 42,636 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Leerink Partnrs Has Positive Outlook of RAPT FY2024 Earnings - Armenian Reporter
FY2024 Earnings Forecast for RAPT Issued By Leerink Partnrs - Defense World
All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy - Yahoo Finance
RAPT Therapeutics Inc (NASDAQ: RAPT) Up 31.9% From 52-Week Low; YTD Falls -26.58% – Here’s What To Do Now - Marketing Sentinel
A stock that deserves closer examination: RAPT Therapeutics Inc (RAPT) - US Post News
A stock that deserves closer examination: Solidion Technology Inc (STI) - US Post News
Analytical Lens: Exploring RAPT Therapeutics Inc (RAPT)’s Financial Story Through Ratios - The Dwinnex
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Recommendation of “Hold” by Brokerages - Defense World
Form 424B3 RAPT Therapeutics, Inc. - StreetInsider.com
SEC Form 424B3 filed by RAPT Therapeutics Inc. - Quantisnow
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull - MSN
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Stake Boosted by Barclays PLC - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Sold by Jane Street Group LLC - Defense World
RAPT Therapeutics Plans Phase 2b Trials for RPT904 - TipRanks
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Purchased by Barclays PLC - Defense World
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
RAPT Therapeutics appoints new board chair By Investing.com - Investing.com Nigeria
Finance Watch: Generation Bio, CytomX Right-Size Operations Ahead Of J.P. Morgan - insights.citeline.com
RAPT Therapeutics appoints new board chair - Investing.com
RAPT Therapeutics, Inc. Announces Board Changes - Marketscreener.com
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors - The Manila Times
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors - GlobeNewswire
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $9.56 Average Target Price from Brokerages - MarketBeat
Rapt Therapeutics Inc (RAPT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):